Aptamers are short DNA or RNA strands that can recognize and bind to a specific target molecule with high precision. Similar to antibodies, they can be used to detect these molecules or modulate their activity. Unlike antibodies, they are much more stable, can be produced synthetically and can be chemically modified to achieve the desired properties. As a result, they can offer capabilities that cannot be achieved with antibodies.

As demand grows for accurate and rapid diagnostic tools, aptamers are often better suited to these applications than antibodies. However, developing aptamers is both experimentally demanding and time-consuming. A team of scientists from IOCB Prague, led by Dr. Marek Ondruš and Prof. Michal Hocek, has now developed a technology that significantly shortens the development process. Their research is published in the journal Nature Communications.